---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-008015"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T14:51:35.520287+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix receives CMS reimbursement determination for DefenCath; sets WAC price at $249.99 per vial

## Summary
- CMS determined DefenCath eligible for ESRD PPS reimbursement; CorMedix submitted TDAPA application for 5-year add-on payment.
- List price (WAC) set at $249.99 per 3mL vial; company committed to reduce price if Part B reimbursement is granted.
- Reiterates inpatient launch target of April 15, 2024; outpatient launch target of July 1, 2024, contingent on CMS TDAPA approval.
- Company will notify CMS to adjust inpatient NTAP reimbursement now that a WAC price is established.

## SEC filing metadata
- accession: 0001213900-24-008015
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390024008015/0001213900-24-008015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390024008015/ea192430-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-008015
- JSON: https://secwatch.observer/filing/0001213900-24-008015.json
- Plain text: https://secwatch.observer/filing/0001213900-24-008015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.